<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31938043</article-id><article-id pub-id-type="pmc">6954503</article-id><article-id pub-id-type="publisher-id">516</article-id><article-id pub-id-type="doi">10.1186/s13098-020-0516-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Report</subject></subj-group></article-categories><title-group><article-title>Impact of sodium&#x02013;glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Akinobu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Miyoshi</surname><given-names>Hideaki</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1870-6688</contrib-id><name><surname>Kameda</surname><given-names>Hiraku</given-names></name><address><email>hirarak@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yamashita</surname><given-names>Kumiko</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kurihara</surname><given-names>Yoshio</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 7691</institution-id><institution-id institution-id-type="GRID">grid.39158.36</institution-id><institution>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, </institution><institution>Hokkaido University Graduate School of Medicine, </institution></institution-wrap>N-15, W-7, Kita-ku, Sapporo, 060-8638 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2173 7691</institution-id><institution-id institution-id-type="GRID">grid.39158.36</institution-id><institution>Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, </institution><institution>Hokkaido University Graduate School of Medicine, </institution></institution-wrap>Sapporo, Japan </aff><aff id="Aff3"><label>3</label>Kurihara Clinic, Sapporo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>12</volume><elocation-id>4</elocation-id><history><date date-type="received"><day>28</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>5</day><month>1</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">We compared the effects of sodium&#x02013;glucose cotransporter 2 (SGLT2) inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease (CKD) classified by degree of albuminuria.</p></sec><sec><title>Methods</title><p id="Par2">A retrospective review of the clinical records of Japanese participants with type 2 diabetes (age&#x02009;&#x0003e;&#x02009;20&#x000a0;years; SGLT2 inhibitor treatment&#x02009;&#x0003e;&#x02009;2&#x000a0;years; estimated glomerular filtration rate (eGFR)&#x02009;&#x0003c;&#x02009;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>) was conducted. Based on the urinary albumin-to-creatinine ratio (UACR) or urinary protein-to-creatinine ratio (UPCR) at the start of SGLT2 inhibitor administration, participants were categorized into three groups: normoalbuminuria (A1; UACR&#x02009;&#x0003c;&#x02009;30&#x000a0;mg/g Cr or UPCR&#x02009;&#x0003c;&#x02009;0.15&#x000a0;g/g Cr), microalbuminuria (A2; UACR 30 to&#x02009;&#x0003c;&#x02009;300&#x000a0;mg/g Cr or UPCR 0.15 to&#x02009;&#x0003c;&#x02009;0.50&#x000a0;g/g Cr), and macroalbuminuria (A3; UACR&#x02009;&#x02265;&#x02009;300&#x000a0;mg/g Cr or UPCR&#x02009;&#x02265;&#x02009;0.50&#x000a0;g/g Cr). The study outcome was a comparison of the rates of change in renal function evaluated by eGFR at 2&#x000a0;years after starting SGLT2 inhibitor among the three groups.</p></sec><sec><title>Results</title><p id="Par3">A total of 87 participants (40 females, 47 males) were categorized into three groups: A1 (<italic>n</italic>&#x02009;=&#x02009;46), A2 (<italic>n</italic>&#x02009;=&#x02009;25), and A3 (<italic>n</italic>&#x02009;=&#x02009;16). eGFR was similarly decreased at 2&#x000a0;years before starting SGLT2 inhibitor in all three groups. However, the decline in eGFR was ameliorated at 2&#x000a0;years after starting SGLT2 inhibitor, and eGFR was rather increased in the A1 and A2 groups. Interestingly, the rate of change in eGFR at 2&#x000a0;years after starting SGLT2 inhibitor in the A1 group was significantly higher than that in the A3 group.</p></sec><sec><title>Conclusions</title><p id="Par4">These results demonstrate that more favorable effects of SGLT2 inhibitors on renal function were observed in participants with type 2 diabetes and CKD with normoalbuminuria compared with those with macroalbuminuria.</p><p id="Par5"><italic>Trial registration</italic> UMIN-CTR: UMIN000035263. Registered 15 December 2018</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic kidney disease</kwd><kwd>Diabetic kidney disease</kwd><kwd>Estimated glomerular filtration rate</kwd><kwd>sodium&#x02013;glucose cotransporter 2 inhibitor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par11">Large randomized clinical trials have indicated that sodium&#x02013;glucose cotransporter 2 (SGLT2) inhibitors can significantly ameliorate renal outcomes in participants with type 2 diabetes at high risk for cardiovascular disease [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, SGLT2 inhibitors were found to reduce the risk of renal disease progression by 45%, and show similar benefits for patients with and without established cardiovascular disease in a systematic review and meta-analysis [<xref ref-type="bibr" rid="CR7">7</xref>]. Although a beneficial effect of SGLT2 inhibitors on the decrease in estimated glomerular filtration rate (eGFR) was observed in participants with type 2 diabetes and chronic kidney disease (CKD) [<xref ref-type="bibr" rid="CR8">8</xref>], it remains unclear whether the renoprotective effects of SGLT2 inhibitors vary depending on the degree of albuminuria. In the present study, we compared the effects of SGLT2 inhibitors on renal function in participants with type 2 diabetes and CKD categorized into three groups: normoalbuminuria, microalbuminuria, and macroalbuminuria.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par12">The analyzed data were obtained from our previous retrospective observational study [<xref ref-type="bibr" rid="CR9">9</xref>]. We conducted a retrospective review of the clinical records of Japanese participants with type 2 diabetes (age&#x02009;&#x0003e;&#x02009;20&#x000a0;years; SGLT2 inhibitor treatment&#x02009;&#x0003e;&#x02009;2&#x000a0;years; eGFR&#x02009;&#x0003c;&#x02009;60&#x000a0;mL/min/1.73&#x000a0;m<sup>2</sup>) in the outpatient center at Kurihara Clinic. Participants were excluded from the study if they had no clear data on eGFR or albuminuria. Participants with type 1 diabetes, and those with poor adherence or interruption of the medication were also excluded. An opt-out consent procedure was used. The study was conducted with approval from the Institutional Review Board of the Japan Clinicians Diabetes Association, and registered with the University Hospital Medical Information Network (UMIN; number UMIN000035263).</p></sec><sec id="Sec4"><title>Study definitions and outcomes</title><p id="Par13">Based on the urinary albumin-to-creatinine ratio (UACR) or urinary protein-to-creatinine ratio (UPCR) at the start of SGLT2 inhibitor administration, participants were categorized into three groups: normoalbuminuria (A1; UACR&#x02009;&#x0003c;&#x02009;30&#x000a0;mg/g Cr or UPCR&#x02009;&#x0003c;&#x02009;0.15&#x000a0;g/g Cr), microalbuminuria (A2; UACR 30 to&#x02009;&#x0003c;&#x02009;300&#x000a0;mg/g Cr or UPCR 0.15 to&#x02009;&#x0003c;&#x02009;0.50&#x000a0;g/g Cr), and macroalbuminuria (A3; UACR&#x02009;&#x02265;&#x02009;300&#x000a0;mg/g Cr or UPCR&#x02009;&#x02265;&#x02009;0.50&#x000a0;g/g Cr) [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The study outcome was a comparison of the rates of change in renal function evaluated by eGFR at 2&#x000a0;years after starting SGLT2 inhibitor (%&#x02206;eGFR&#x02009;+&#x02009;2y) among the three groups. As previously described [<xref ref-type="bibr" rid="CR9">9</xref>], &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y and &#x000a0;%&#x02206;eGFR&#x02009;&#x02212;&#x02009;2y were calculated as follows: &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y&#x02009;=&#x02009;[(eGFR at 2&#x000a0;years after starting SGLT2 inhibitor)&#x02009;&#x02212;&#x02009;(eGFR at start of SGLT2 inhibitor)]/(eGFR at start of SGLT2 inhibitor); &#x000a0;%&#x02206;eGFR&#x02013;2y&#x02009;=&#x02009;[(eGFR at start of SGLT2 inhibitor)&#x02009;&#x02212;&#x02009;(eGFR at 2&#x000a0;years before starting SGLT2 inhibitor)]/(eGFR at 2&#x000a0;years before starting SGLT2 inhibitor).</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par14">Data were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation or median. Differences in baseline characteristics and changes among the three groups were compared by one-way analysis of variance followed by post hoc Bonferroni test or the Chi square test, as appropriate. Simple linear regression analyses were performed to test for associations between &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y and baseline HbA1c or change in HbA1c. Values of <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 were considered to indicate statistical significance. All statistical analyses were performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) and Microsoft Excel Statistics 2012 for Windows (SSRI Co. Ltd, Tokyo, Japan).</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par15">A total of 87 participants (40 females, 47 males) were divided into the three groups as follows (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>): A1 (<italic>n</italic>&#x02009;=&#x02009;46), A2 (<italic>n</italic>&#x02009;=&#x02009;25), and A3 (<italic>n</italic>&#x02009;=&#x02009;16). The baseline characteristics of the participants are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. There were no significant differences among the three groups in most of the parameters, including sex, age, body mass index (BMI), duration of diabetes, eGFR, and blood pressure. However, HbA1c level in the A3 group was significantly higher than that in the A1 group.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Flow diagram of the analysis in the study. <italic>eGFR</italic> estimated glomerular filtration rate, <italic>SGLT2</italic> sodium&#x02013;glucose cotransporter 2</p></caption><graphic xlink:href="13098_2020_516_Fig1_HTML" id="MO1"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline characteristics of the 87 participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">A1</th><th align="left">A2</th><th align="left">A3</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left"><italic>n</italic></td><td align="left">46</td><td align="left">25</td><td align="left">16</td><td align="left"/></tr><tr><td align="left">Sex (male/female)</td><td align="left">21/25</td><td align="left">16/9</td><td align="left">10/6</td><td char="." align="char">0.251</td></tr><tr><td align="left">Age (years)</td><td align="left">67.0&#x02009;&#x000b1;&#x02009;8.9</td><td align="left">66.8&#x02009;&#x000b1;&#x02009;7.0</td><td align="left">63.3&#x02009;&#x000b1;&#x02009;8.9</td><td char="." align="char">0.287</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">29.8&#x02009;&#x000b1;&#x02009;6.7</td><td align="left">29.0&#x02009;&#x000b1;&#x02009;4.2</td><td align="left">28.3&#x02009;&#x000b1;&#x02009;4.2</td><td char="." align="char">0.632</td></tr><tr><td align="left">Body weight (kg)</td><td align="left">75.5&#x02009;&#x000b1;&#x02009;18.6</td><td align="left">76.9&#x02009;&#x000b1;&#x02009;13.4</td><td align="left">74.0&#x02009;&#x000b1;&#x02009;12.2</td><td char="." align="char">0.859</td></tr><tr><td align="left">Duration of diabetes (years)</td><td align="left">14.6&#x02009;&#x000b1;&#x02009;6.7</td><td align="left">15.8&#x02009;&#x000b1;&#x02009;7.6</td><td align="left">18.0&#x02009;&#x000b1;&#x02009;8.8</td><td char="." align="char">0.284</td></tr><tr><td align="left">HbA1c (%)</td><td align="left">7.1&#x02009;&#x000b1;&#x02009;0.7</td><td align="left">7.2&#x02009;&#x000b1;&#x02009;0.8</td><td align="left">7.8&#x02009;&#x000b1;&#x02009;1.0 *</td><td char="." align="char">0.015</td></tr><tr><td align="left">eGFR (mL/min/1.73&#x000a0;m<sup>2</sup>)</td><td align="left">47.2&#x02009;&#x000b1;&#x02009;8.7</td><td align="left">48.5&#x02009;&#x000b1;&#x02009;8.8</td><td align="left">42.5&#x02009;&#x000b1;&#x02009;9.6</td><td char="." align="char">0.105</td></tr><tr><td align="left">Category of GFR (G3a/G3b/G4)</td><td align="left">27/18/1</td><td align="left">18/6/1</td><td align="left">9/6/1</td><td char="." align="char">0.681</td></tr><tr><td align="left">Systolic blood pressure (mmHg)</td><td align="left">127.6&#x02009;&#x000b1;&#x02009;8.9</td><td align="left">130.6&#x02009;&#x000b1;&#x02009;11.5</td><td align="left">131.2&#x02009;&#x000b1;&#x02009;10.8</td><td char="." align="char">0.323</td></tr><tr><td align="left">Diastolic blood pressure (mmHg)</td><td align="left">74.3&#x02009;&#x000b1;&#x02009;7.7</td><td align="left">72.9&#x02009;&#x000b1;&#x02009;10.6</td><td align="left">73.8&#x02009;&#x000b1;&#x02009;7.1</td><td char="." align="char">0.813</td></tr><tr><td align="left">ARB or ACE-I (%)</td><td align="left">82.6</td><td align="left">96.0</td><td align="left">100.0</td><td align="left"/></tr><tr><td align="left" colspan="5">SGLT2 inhibitor (%)</td></tr><tr><td align="left">&#x000a0;Canagliflozin</td><td align="left">23.9</td><td align="left">12.0</td><td align="left">37.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;Dapagliflozin</td><td align="left">13.0</td><td align="left">8.0</td><td align="left">6.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Empagliflozin</td><td align="left">8.7</td><td align="left">4.0</td><td align="left">12.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;Ipragliflozin</td><td align="left">4.3</td><td align="left">20.0</td><td align="left">18.8</td><td align="left"/></tr><tr><td align="left">&#x000a0;Luseogliflozin</td><td align="left">6.5</td><td align="left">20.0</td><td align="left">6.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Tofogliflozin</td><td align="left">43.5</td><td align="left">36.0</td><td align="left">18.8</td><td align="left"/></tr><tr><td align="left" colspan="5">Other oral hypoglycemic agents (%)</td></tr><tr><td align="left">&#x000a0;Sulfonylurea</td><td align="left">50.0</td><td align="left">52.0</td><td align="left">62.5</td><td align="left"/></tr><tr><td align="left">&#x000a0;Biguanide</td><td align="left">71.7</td><td align="left">80.0</td><td align="left">93.8</td><td align="left"/></tr><tr><td align="left">&#x000a0;Thiazolidinedione</td><td align="left">2.2</td><td align="left">8.0</td><td align="left">14.3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Alpha-glucosidase inhibitor</td><td align="left">15.0</td><td align="left">20.0</td><td align="left">0.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;Glinide</td><td align="left">0.0</td><td align="left">0.0</td><td align="left">0.0</td><td align="left"/></tr><tr><td align="left">&#x000a0;DPP-4 inhibitor</td><td align="left">50.0</td><td align="left">76.0</td><td align="left">62.5</td><td align="left"/></tr><tr><td align="left">Insulin (%)</td><td align="left">13.0</td><td align="left">12.0</td><td align="left">25.0</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD</p><p><italic>ACE-I</italic> angiotensin-converting enzyme inhibitor, <italic>ARB</italic> angiotensin II receptor blocker, <italic>DPP-4</italic> dipeptidyl peptidase-4, <italic>eGFR</italic> estimated glomerular filtration rate, <italic>SGLT2</italic> sodium&#x02013;glucose cotransporter 2</p><p>*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. A1 group</p></table-wrap-foot></table-wrap>
</p><p id="Par16">As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, eGFR was similarly decreased at 2&#x000a0;years before starting SGLT2 inhibitor in all three groups (%&#x02206;eGFR&#x02009;&#x02212;&#x02009;2y: &#x02212;&#x02009;10.8%&#x02009;&#x000b1;&#x02009;13.5% in A1 group, &#x02212;&#x02009;5.1%&#x02009;&#x000b1;&#x02009;12.6% in A2 group, &#x02212;&#x02009;12.8&#x02009;&#x000b1;&#x02009;14.7% in A3 group; <italic>P</italic>&#x02009;=&#x02009;0.135). However, the decline in eGFR was ameliorated at 2&#x000a0;years after starting SGLT2 inhibitor, and eGFR was rather increased in the A1 and A2 groups. Interestingly, &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y in the A1 group was significantly higher than that in the A3 group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y was not associated with baseline HbA1c (correlation coefficient: 0.068, <italic>P</italic>&#x02009;=&#x02009;0.532) or change in HbA1c (correlation coefficient: &#x02212;&#x02009;0.101, <italic>P</italic>&#x02009;=&#x02009;0.353).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Serial changes in estimated glomerular filtration rate (eGFR) at 2&#x000a0;years before and after starting sodium&#x02013;glucose cotransporter 2 (SGLT2) inhibitor in participants with type 2 diabetes and chronic kidney disease in three groups: normoalbuminuria (A1; <italic>n</italic>&#x02009;=&#x02009;46), microalbuminuria (A2; <italic>n</italic>&#x02009;=&#x02009;25), and macroalbuminuria (A3; <italic>n</italic>&#x02009;=&#x02009;16). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. A3, one-way analysis of variance followed by post hoc Bonferroni test</p></caption><graphic xlink:href="13098_2020_516_Fig2_HTML" id="MO2"/></fig>
<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Rates of change in estimated glomerular filtration rate (eGFR) at 2&#x000a0;years after starting sodium&#x02013;glucose cotransporter 2 (SGLT2) inhibitor (%&#x02206;eGFR&#x02009;+&#x02009;2y) in participants with type 2 diabetes and chronic kidney disease in three groups: normoalbuminuria (A1; <italic>n</italic>&#x02009;=&#x02009;46), microalbuminuria (A2; <italic>n</italic>&#x02009;=&#x02009;25), and macroalbuminuria (A3; <italic>n</italic>&#x02009;=&#x02009;16). *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 between A1 and A3 group, one-way analysis of variance followed by post hoc Bonferroni test</p></caption><graphic xlink:href="13098_2020_516_Fig3_HTML" id="MO3"/></fig>
</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par17">The present results indicated that &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y in the A1 group was significantly higher than that in the A3 group. Because baseline HbA1c in the A1 group was lower than that in the A3 group, we assumed that glucose tolerance could affect &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y. However, there was no association between &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y and baseline HbA1c or change in HbA1c at 2&#x000a0;years. These data suggest that glucose tolerance is not related to &#x000a0;%&#x02206;eGFR&#x02009;+&#x02009;2y. Recently, it was reported that the incidence of low eGFR with normoalbuminuria has been increasing in type 2 diabetes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Pathological findings revealed that tubulointerstitial and vascular lesions tended to be more advanced in participants with type 2 diabetes and CKD with normoalbuminuria than those in participants with microalbuminuria or macroalbuminuria [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Because the possible mechanisms for the renoprotective effects of SGLT2 inhibitors are assumed to include not only reduction in glomerular hyperfiltration as a result of tubuloglomerular feedback restoration, but also improvement of tubulointerstitial damage [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], improved tubular cell injury may contribute to the greater beneficial effects of SGLT2 inhibitors in participants with type 2 diabetes and CKD with normoalbuminuria. Recent reports have shown a putative protective effect of SGLT2 inhibitors against tubular cell injury. In in vitro studies of proximal tubular cells, SGLT2 inhibitors suppressed the hyperglycemia-induced production of reactive oxygen species and angiotensinogen [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. In mice fed a high-fat diet, ipragliflozin improved proximal tubular cell integrity by reducing mitochondrial damage [<xref ref-type="bibr" rid="CR20">20</xref>]. Furthermore, a cross-over clinical study showed that treatment with dapagliflozin reduced the urinary excretion of markers of tubular injury and inflammatory markers in participants with type 2 diabetes [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par18">The main limitations of the present study are its retrospective design and relatively small sample. Other limitations are the relatively short follow-up duration and the study endpoint of changes in renal function evaluated by eGFR, rather than hard endpoints such as initiation of renal-replacement therapy or death from renal disease. Further studies are needed to verify our results in a prospective larger cohort for a longer observational period.</p></sec><sec id="Sec8"><title>Conclusions</title><p id="Par19">In conclusion, our study demonstrated that more favorable effects of SGLT2 inhibitors on renal function were observed in participants with type 2 diabetes and CKD with normoalbuminuria than in participants with macroalbuminuria. These findings suggest that the renoprotective effects of SGLT2 inhibitors in participants with CKD can vary depending on the degree of albuminuria.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CKD</term><def><p id="Par6">chronic kidney disease</p></def></def-item><def-item><term>eGFR</term><def><p id="Par7">estimated glomerular filtration rate</p></def></def-item><def-item><term>SGLT2</term><def><p id="Par8">sodium&#x02013;glucose cotransporter 2</p></def></def-item><def-item><term>UACR</term><def><p id="Par9">urinary albumin-to-creatinine ratio</p></def></def-item><def-item><term>UPCR</term><def><p id="Par10">urinary protein-to-creatinine ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank the participants at Kurihara Clinic. We also thank Alison Sherwin, PhD, from Edanz Group (<ext-link ext-link-type="uri" xlink:href="http://www.edanzediting.com/ac">http://www.edanzediting.com/ac</ext-link>) for editing a draft of this manuscript.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AN contributed in writing the manuscript. AN, HK and KY contributed to the data analysis. AN, HY, HK and YK contributed to the discussion, and reviewed and edited the manuscript. HK is the guarantor of this work and, as such, had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study did not supported by anywhere.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par20">The study was conducted with approval from the Institutional Review Board of the Japan Clinicians Diabetes Association, and registered with the University Hospital Medical Information Network (UMIN; number UMIN000035263).</p></notes><notes><title>Consent for publication</title><p id="Par21">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par22">AN. has obtained research support from Mitsubishi Tanabe Pharma Co. and Ono Pharmaceutical Co. Ltd. H.M. has received honoraria for lectures from Astellas Pharma Inc., Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., MSD, Novartis Pharma, Novo Nordisk Pharma, Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Sanofi, and has received research funding from Astellas Pharma Inc., Daiichi Sankyo, Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., Novo Nordisk Pharma, Kowa Pharmaceutical Co., Abbott Japan Co., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Taisho Pharmaceutical Co. Ltd. Y.K. has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca, Mitsubishi Tanabe Pharma Co. Ltd., MSD, Ono Pharmaceutical Co. Ltd., Sanofi, Shionogi &#x00026; Co. Ltd., Taisho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. H.K. and K.Y.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanner</surname><given-names>C</given-names></name><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Empagliflozin and progression of kidney disease in type 2 diabetes</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1515920</pub-id><pub-id pub-id-type="pmid">27299675</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherney</surname><given-names>DZI</given-names></name><name><surname>Zinman</surname><given-names>B</given-names></name><name><surname>Inzucchi</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial</article-title><source>Lancet Diab Endocrinol.</source><year>2017</year><volume>5</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(17)30182-1</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Canagliflozin and cardiovascular and renal events in type 2 diabetes</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>644</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1611925</pub-id><pub-id pub-id-type="pmid">28605608</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>de Zeeuw</surname><given-names>D</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials</article-title><source>Lancet Diab Endocrinol.</source><year>2018</year><volume>6</volume><fpage>691</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(18)30141-4</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Bonaca</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Dapagliflozin and cardiovascular outcomes in type 2 diabetes</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1812389</pub-id><pub-id pub-id-type="pmid">30415602</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mosenzon</surname><given-names>O</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Cahn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial</article-title><source>Lancet Diab Endocrinol.</source><year>2019</year><volume>7</volume><fpage>606</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(19)30180-9</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelniker</surname><given-names>TA</given-names></name><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Raz</surname><given-names>I</given-names></name><etal/></person-group><article-title>SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials</article-title><source>Lancet</source><year>2019</year><volume>393</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32590-X</pub-id><pub-id pub-id-type="pmid">30424892</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkovic</surname><given-names>V</given-names></name><name><surname>Jardine</surname><given-names>MJ</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><etal/></person-group><article-title>Canagliflozin and renal outcomes in type 2 diabetes and nephropathy</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><fpage>2295</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1811744</pub-id><pub-id pub-id-type="pmid">30990260</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Kameda</surname><given-names>H</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name><etal/></person-group><article-title>Protective effect of sodium&#x02013;glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes</article-title><source>J Diab Invest.</source><year>2019</year><volume>10</volume><fpage>1510</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.1111/jdi.13064</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kume</surname><given-names>S</given-names></name><name><surname>Araki</surname><given-names>SI</given-names></name><name><surname>Ugi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014</article-title><source>J Diab Invest.</source><year>2019</year><volume>10</volume><fpage>1032</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1111/jdi.12977</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Furuichi</surname><given-names>K</given-names></name><name><surname>Toyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy</article-title><source>Diab Care</source><year>2013</year><volume>36</volume><fpage>3655</fpage><lpage>3662</lpage><pub-id pub-id-type="doi">10.2337/dc13-0298</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afkarian</surname><given-names>M</given-names></name><name><surname>Zelnick</surname><given-names>LR</given-names></name><name><surname>Hall</surname><given-names>YN</given-names></name><etal/></person-group><article-title>Clinical manifestations of kidney disease among us adults with diabetes, 1988&#x02013;2014</article-title><source>JAMA</source><year>2016</year><volume>316</volume><fpage>602</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.10924</pub-id><pub-id pub-id-type="pmid">27532915</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Kodera</surname><given-names>R</given-names></name><name><surname>Utsunomiya</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prevalence of albuminuria and renal dysfunction and related clinical factors in Japanese patients with diabetes: the Japan diabetes complication and its prevention prospective study (JDCP study 5)</article-title><source>J Diab Invest.</source><year>2019</year><pub-id pub-id-type="doi">10.1111/jdi.13116</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekinci</surname><given-names>EI</given-names></name><name><surname>Jerums</surname><given-names>G</given-names></name><name><surname>Skene</surname><given-names>A</given-names></name><etal/></person-group><article-title>Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function</article-title><source>Diab Care</source><year>2013</year><volume>36</volume><fpage>3620</fpage><lpage>3626</lpage><pub-id pub-id-type="doi">10.2337/dc12-2572</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Furuichi</surname><given-names>K</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><etal/></person-group><article-title>Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency</article-title><source>Clin Exp Nephrol</source><year>2014</year><volume>18</volume><fpage>305</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1007/s10157-013-0870-0</pub-id><pub-id pub-id-type="pmid">24081589</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alicic</surname><given-names>RZ</given-names></name><name><surname>Neumiller</surname><given-names>JJ</given-names></name><name><surname>Johnson</surname><given-names>EJ</given-names></name><etal/></person-group><article-title>sodium&#x02013;glucose cotransporter 2 inhibition and diabetic kidney disease</article-title><source>Diabetes</source><year>2019</year><volume>68</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.2337/dbi18-0007</pub-id><pub-id pub-id-type="pmid">30665953</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dekkers</surname><given-names>CCJ</given-names></name><name><surname>Petrykiv</surname><given-names>S</given-names></name><name><surname>Laverman</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers</article-title><source>Diab Obes Metab</source><year>2018</year><volume>20</volume><fpage>1988</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1111/dom.13301</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>T</given-names></name><name><surname>Yamagishi</surname><given-names>S</given-names></name></person-group><article-title>Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation</article-title><source>Horm Metab Res</source><year>2016</year><volume>48</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">26158396</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satou</surname><given-names>R</given-names></name><name><surname>Cypress</surname><given-names>MW</given-names></name><name><surname>Woods</surname><given-names>TC</given-names></name><etal/></person-group><article-title>Blockade of sodium glucose cotransporter 2 suppresses high glucose induced angiotensinogen augmentation in renal proximal tubular cells</article-title><source>Am J Physiol Renal Physiol</source><year>2019</year><pub-id pub-id-type="doi">10.1152/ajprenal.00402.2019</pub-id><pub-id pub-id-type="pmid">31682172</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Takagaki</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet</article-title><source>J Diab Invest.</source><year>2018</year><volume>9</volume><fpage>1025</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.1111/jdi.12802</pub-id></element-citation></ref></ref-list></back></article>